New anticoagulants for treatment of venous thromboembolismPeter L Gross
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Arterioscler Thromb Vasc Biol 28:380-6. 2008
....
- Zinc: an important cofactor in haemostasis and thrombosis
Trang T Vu
Thrombosis and Atherosclerosis Research Institute, Department of Medical Sciences, McMaster University, 237 Barton St E, Hamilton, Ontario L8L 2X2, Canada
Thromb Haemost 109:421-30. 2013
..This paper reviews the mechanisms by which zinc regulates coagulation, platelet aggregation, anticoagulation and fibrinolysis and outlines how zinc serves as a ubiquitous modulator of haemostasis and thrombosis...
- New oral anticoagulants: which one should my patient use?
Jeffrey I Weitz
Department of Medicine, McMaster University, Hamilton, ON, Canda
Hematology Am Soc Hematol Educ Program 2012:536-40. 2012
....
Oral direct factor Xa inhibitorsCalvin H Yeh
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Circ Res 111:1069-78. 2012
..Thus, the long path to finding replacements for warfarin has finally reached fruition. Therefore, development of the oral factor Xa inhibitors represents a translational science success story...
- New oral anticoagulants: a view from the laboratory
Jeffrey I Weitz
Department of Medicine, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
Am J Hematol 87:S133-6. 2012
....
New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesJeffrey I Weitz
Thrombosis and Atherosclerosis Research Institute and Department of Medicine, McMaster University, Hamilton, ON, Canada
Chest 141:e120S-51S. 2012
....
- A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery
Jeffrey I Weitz
Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada
Thromb Haemost 104:1150-7. 2010
..All TAK-442 doses except 10 and 20 mg BID displayed similar efficacy and safety profiles to enoxaparin...
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Jeffrey I Weitz
Thrombosis and Atherosclerosis Research Institute, Hamilton General Hospital, Ontario, Canada
Thromb Haemost 104:633-41. 2010
..In contrast, the edoxaban bid regimens were associated with more bleeding than warfarin. These results suggest that in this three-month study, edoxaban 30 or 60 mg qd are safe and well-tolerated...
- Potential of new anticoagulants in patients with cancer
Jeffrey I Weitz
Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Henderson Research Centre, Ontario, Canada
Thromb Res 125:S30-5. 2010
..In the coming years, these drugs are likely to replace warfarin for most indications. This paper addresses their potential role for prevention and treatment of cancer-related thrombosis...
- Factor Xa and thrombin as targets for new oral anticoagulants
Jeffrey I Weitz
Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University and Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada
Thromb Res 127:S5-S12. 2011
..The new agents produce such a predictable anticoagulant response that they can be given in fixed doses without monitoring. This paper focuses on the new oral anticoagulants in the most advanced stages of development...
- New anticoagulants
J I Weitz
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
J Thromb Haemost 3:1843-53. 2005
..After a brief review of coagulation pathways, this paper focuses on new anticoagulants in advanced stages of clinical testing...
- Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results
S S Anand
From the Preventive Cardiology and Therapeutics Program, Hamilton Civics Hospital Research Centre, and Division of Cardiology, McMaster University, Hamilton, Canada
Circulation 98:1064-70. 1998
..We studied the effects of long-term warfarin at 2 intensities in patients with AIS without ST elevation in 2 consecutive randomized controlled studies...
- Vasoflux, a new anticoagulant with a novel mechanism of action
J I Weitz
Hamilton Civic Hospitals Reseach Centre, Hamilton, Ontario, Canada
Circulation 99:682-9. 1999
..Heparin does not inactivate fibrin-bound thrombin, whereas hirudin fails to block thrombin generation. In contrast, Vasoflux is a novel anticoagulant that inactivates fibrin-bound thrombin and attenuates factor Xa generation...
- Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction
J I Weitz
Department of Medicine, McMaster University, Hamilton Civic Hospital Research Center, Ontario, Canada
Arch Intern Med 160:749-58. 2000
..We focus on the opportunities presented by these agents, detailing mechanisms of action, advantages over aspirin and heparin, and performance in recent clinical trials...
- Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase
J A Anderson
Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 276:9755-61. 2001
..These studies reveal that sLA-LMWH acts as a potent antithrombin-independent inhibitor of coagulation by attenuating intrinsic tenase and prothrombinase...
- Clinical utility of a rapid whole-blood D-dimer assay in patients with cancer who present with suspected acute deep venous thrombosis
A Y Lee
McMaster University, Hamilton, Ontario, Canada
Ann Intern Med 131:417-23. 1999
..Although D-dimer assays have high negative predictive values for the diagnosis of deep venous thrombosis, their accuracy in patients with cancer is uncertain...
- Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin
T J Podor
Department of Pathology and Molecular Medicine, McMaster University and the Hamilton Civic Hospitals Research Centre, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 275:19788-94. 2000
..These findings indicate that plasma PAI-1.vitronectin complexes can be localized to the surface of fibrin clots; by this localization, they may modulate fibrinolysis and clot reorganization...
- Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study
M A Crowther
Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada
Thromb Haemost 85:390-4. 2001
..Our study also confirms that patients with idiopathic venous thromboembolism have a high risk of recurrence...
- Heparin compromises streptokinase-induced arterial patency in rabbits
M Vlasin
Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
Thromb Res 115:427-34. 2005
..CONCLUSIONS: Our findings suggest that caution needs to be exercised, when using the combination of SK and heparinoids for the treatment of arterial thrombosis under conditions of severe vascular damage and stenosis...
- Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin
S M Bates
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Arch Intern Med 161:385-91. 2001
..We sought to identify an aPTT ratio that corresponds to therapeutic anti--factor Xa heparin levels for combinations of several reagents and coagulometers that are commonly used...
- Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor ii in the presence of dermatan sulfate but not heparin
P C Liaw
McMaster University and the Henderson Research Centre, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 276:20959-65. 2001
..Consequently, thrombin remains susceptible to inactivation by heparin cofactor II. This study explains why fibrin-bound thrombin is susceptible to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin...
- Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2)study
J W Eikelboom
Preventive Cardiology and Therapeutics Program, McMaster University, Hamilton, Canada
Circulation 103:643-50. 2001
..The excess of major bleeding in hirudin-treated patients who develop thrombocytopenia suggests that thrombocytopenia may contribute to the increased risk of bleeding observed with hirudin...
- Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin
A Y Lee
Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Ontario, Canada
Thromb Haemost 85:502-8. 2001
..This provides a mechanism to limit the concentration of (DD)E and maintain the fibrin-specificity of t-PA...
- New antithrombotic drugs
P L Gross
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Clin Pharmacol Ther 86:139-46. 2009
..This paper focuses on these new targets and new antiplatelet drugs and anticoagulants and describes the major advances in the continuing search for more potent antithrombotic drugs that have limited effects on hemostasis...
- Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors
J I Weitz
Department of Medicine, McMaster University and Hamilton Civic Hospitals Research Centre, Ontario, Canada
Circulation 97:544-52. 1998
..Thrombolytic therapy induces a procoagulant state characterized by elevated plasma levels of fibrinopeptide A (FPA), but the responsible mechanism is uncertain...
- New oral anticoagulants in development
Jeffrey I Weitz
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Thromb Haemost 103:62-70. 2010
..This paper focuses on the new oral anticoagulants in the most advanced stages of development...
- Conformational changes in thrombin when complexed by serpins
J C Fredenburgh
Hamilton Civic Hospitals Research Centre and Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 276:44828-34. 2001
..The disorganization of exosite 1 that occurs when thrombin is complexed by serpins is consistent with results of protease sensitivity studies and crystallographic analysis of a homologous enzyme-serpin complex...
- The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model
P Klement
McMaster University and Henderson Research Center, Hamilton, Ontario, Canada
J Thromb Haemost 1:587-94. 2003
..Thus, at maximally effective doses, melagatran causes less bleeding than hirudin in this model. These findings raise the possibility that some direct thrombin inhibitors are safer than others...
- New anticoagulant drugs
J I Weitz
Hamilton Civic Hospitals Research Center and McMaster University, Hamilton, Ontario L8V 1C3, Canada
J Thromb Thrombolysis 12:7-17. 2001
..This paper (1) reviews arterial and venous thrombogenesis, (2) outlines new anticoagulant strategies, and (3) provides clinical perspectives on these new strategies...
- Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor
C Kearon
McMaster University, Hamilton, Ontario, Canada
J Thromb Haemost 2:743-9. 2004
..Retrospective analyses suggest that 1 month of anticoagulation is adequate for patients whose venous thromboembolic event was provoked by a transient risk factor...
- Meeting the unmet needs in anticoagulant therapy
Jeffrey I Weitz
Thrombosis and Atherosclerosis Research Institute, Hamilton General Hospital, Hamilton, ON, Canada
Eur J Haematol 85:p1-28. 2010
..Designed to be given in fixed doses without routine anticoagulation monitoring, these new agents have the potential to revolutionize long-term anticoagulation therapy...
- Unanswered questions in venous thromboembolism
Jeffrey I Weitz
Departments of Medicine and Biochemistry, McMaster University, Henderson Research Centre, Hamilton, Ontario, Canada
Thromb Res 123:S2-S10. 2009
..In addition, the new agents have the potential to streamline extended VTE therapy because, unlike vitamin K antagonists, they can be given in fixed doses without the need for coagulation monitoring...
- New anticoagulants
Lori-Ann Linkins
Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
Semin Thromb Hemost 29:619-31. 2003
....
- Selective factor Xa inhibition for thromboprophylaxis
John W Eikelboom
McMaster University, Hamilton, ON, Canada
Lancet 372:6-8. 2008
- Coagulation assays
Shannon M Bates
Department of Medicine, McMaster University, Henderson Research Centre, Hamilton, Ontario, Canada
Circulation 112:e53-60. 2005
- Factor Xa or thrombin: is thrombin a better target?
J I Weitz
Henderson Research Centre and McMaster University, Hamilton, ON, Canada
J Thromb Haemost 5:65-7. 2007
..Several oral factor Xa inhibitors also are being tested. Is thrombin a better target for new oral anticoagulants than factor Xa? Only time will tell!..
- New anticoagulants: an update
Mark Crowther
Division of Hematology, St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
Clin Adv Hematol Oncol 2:743-9. 2004
....
- Emerging anticoagulants for the treatment of venous thromboembolism
Jeffrey I Weitz
Department of Medicine, McMaster University, Hamiton, Ontario, Canada
Thromb Haemost 96:274-84. 2006
....
- Update on heparin: what do we need to know?
Daniel S Weitz
Department of Medicine, McMaster University, and Henderson Research Centre, Hamilton, ON, Canada
J Thromb Thrombolysis 29:199-207. 2010
....
- Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial
Shamir R Mehta
McMaster University and the Population Health Research Institute, Hamilton Health Sciences, General Division, 237 Barton St E, Hamilton, Ontario, Canada L6K 1B8
Circulation 111:1390-7. 2005
..We performed a randomized trial to determine the safety and feasibility of fondaparinux in the percutaneous coronary intervention (PCI) setting...
- New anticoagulant therapy
Lori Ann Linkins
McMaster University and Henderson Research Center, Hamilton, Ontario, Canada L8V 1C3
Annu Rev Med 56:63-77. 2005
..This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants...
- Beyond heparin and warfarin: the new generation of anticoagulants
Jeffrey I Weitz
McMaster University and Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, L8V 1C3, Canada
Expert Opin Investig Drugs 16:271-82. 2007
....
- A Protease TAMER: a nucleic acid-based anticoagulant
J C Fredenburgh
Departments of Medicine and Biochemistry and Biomedical Sciences and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada
J Thromb Haemost 10:867-9. 2012
..See also Bompiani KM, Monroe DM, Church FC, Sullenger BA. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity. This issue, pp 870-80...
- Homocysteine-dependent alterations in mitochondrial gene expression, function and structure. Homocysteine and H2O2 act synergistically to enhance mitochondrial damage
R C Austin
Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 273:30808-17. 1998
..Furthermore, our findings suggest that intracellular glutathione and heat shock proteins play a role in protecting mitochondria against the adverse effects elicited by homocysteine and H2O2...
- New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin
Shannon M Bates
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Br J Pharmacol 144:1017-28. 2005
..After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing...
- New anticoagulants for treatment of venous thromboembolism
Jeffrey I Weitz
McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Circulation 110:I19-26. 2004
..The lack of an antidote for these new agents is a drawback, particularly for idraparinux, which has a long half-life...
- Direct thrombin inhibitors
Jeffrey I Weitz
McMaster University and Henderson Research Centre, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3
Thromb Res 106:V275-84. 2002
..This review summarizes the clinical trial data with direct thrombin inhibitors and provides perspective on the role of direct thrombin inhibitors in the face of other new anticoagulants currently under development...
- HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions
Colin A Kretz
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Thromb Haemost 103:83-93. 2010
..These findings identify prothrombin as a potential target for new anticoagulants...
- In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation
Lori Ann Linkins
Henderson Research Centre and McMaster University, 711 Concession Street, Hamilton, Ontario, Canada L8V 1C3
Thromb Res 107:241-4. 2002
..The ACT and aPTT therefore cannot be used to monitor low-molecular weight heparin or fondaparinux, highlighting the need for a point-of-care anti-factor Xa assay...
- Antithrombin-independent anticoagulation by hypersulfated low-molecular-weight heparin
James C Fredenburgh
Henderson Research Centre, Hamilton, Ontario, Canada
Trends Cardiovasc Med 12:281-7. 2002
..In a rabbit carotid artery thrombosis prevention model, sLA-LMWH is superior to LMWH. Because of its low affinity for antithrombin and multiple sites of action, sLA-LMWH may prove to be safer and more effective than other anticoagulants...
- Direct thrombin inhibitors in acute coronary syndromes: present and future
Jeffrey I Weitz
McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Circulation 105:1004-11. 2002
- Changing paradigms in the management of venous thromboembolism
Jeffrey I Weitz
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Am Heart Hosp J 4:135-41. 2006
- Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin
Amy V L Schaefer
Department of Medicine, McMaster University, Hamilton, Ontario L8V 1C3, Canada
Biochemistry 45:4257-65. 2006
..These data suggest that structural changes resulting from incorporation of fragment X into clots promote their lysis. Thus, attenuation of thrombolytic therapy-induced fragment X formation may reduce the risk of bleeding...
- Acute coronary syndromes: a focus on thrombin
Jeffrey I Weitz
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
J Invasive Cardiol 14:2B-7B. 2002
- New anticoagulants: current status and future potential
Jeffrey I Weitz
Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Am J Cardiovasc Drugs 3:201-9. 2003
....
- A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis
Shannon M Bates
McMaster University Medical Centre, HSC 3W11, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada
Ann Intern Med 138:787-94. 2003
..Because clinical diagnosis is inaccurate, objective testing is usually considered necessary when patients present with suspected deep venous thrombosis (DVT)...
- Emerging anticoagulant drugs
Shannon M Bates
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Arterioscler Thromb Vasc Biol 23:1491-500. 2003
..After a brief review of thrombogenesis and its regulation, this study focuses on new anticoagulant agents in more advanced stages of clinical testing...
- Multimerin 1 binds factor V and activated factor V with high affinity and inhibits thrombin generation
Samira B Jeimy
Department of Pathology and Molecular Medicine, Health Sciences Center, McMaster University, 1200 Main St West, Hamilton, Ontario, Canada, L8N 3Z5
Thromb Haemost 100:1058-67. 2008
..The high affinity binding of FV to MMRN1 may facilitate the costorage of the two proteins in platelet alpha-granules. As a consequence, MMRN1 release during platelet activation may limit platelet dependent thrombin generation in vivo...
- Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide
Ericka M Wiebe
Henderson Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada
J Biol Chem 278:35767-74. 2003
..IXa. Furthermore, our data suggest that the efficacy of pentasaccharide for prevention and treatment of thrombotic disorders may reflect its action at two sites in the coagulation system...
- Leukocyte urokinase plasminogen activator receptor and PSGL1 play a role in endogenous arterial fibrinolysis
Xufang Bai
Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
Thromb Haemost 102:1212-8. 2009
..Thus, fibrin loss from microarteriolar thrombi is mediated, at least in part, by leukocyte-associated uPA in a process that requires leukocyte uPAR and PSGL-1...
- Glycosaminoglycans bind factor Xa in a Ca2+-dependent fashion and modulate its catalytic activity
Alan R Stafford
Henderson Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada
Biochemistry 42:13091-8. 2003
..These studies suggest that glycosaminoglycan binding perturbs exosites on the surface of factor Xa, potentially modifying interactions with cofactors or substrates...
- New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Jeffrey I Weitz
Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
Chest 126:265S-286S. 2004
....
- Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapy
Joanne L Yu
Henderson Research Centre, Experimental Thrombosis Research, McMaster University, Hamilton, Ontario, Canada
Semin Thromb Hemost 30:21-30. 2004
..Therefore, direct targeting of TF in cancer should be considered in combination with other treatment modalities such as oncogene-directed therapies, antiangiogenic agents (e.g., VEGF antagonists), and anti-cancer chemotherapy...
- Novel antithrombotic therapies for the prevention of stroke in patients with atrial fibrillation
Jeffrey I Weitz
Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada
Am J Manag Care 10:S72-82. 2004
....
- Pharmacology and clinical potential of direct thrombin inhibitors
Lori-Ann Linkins
McMaster University and Henderson Research Centre, Hamilton, Ontario, L8V 1C3, Canada
Curr Pharm Des 11:3877-84. 2005
....
- An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial
Clive Kearon
McMaster University and the Henderson Research Centre, Hamilton, Ontario, Canada
Ann Intern Med 144:812-21. 2006
..It may be safe to omit additional diagnostic testing in selected patients with suspected pulmonary embolism (PE) who have a negative D-dimer test, but this approach has never been evaluated in a randomized, controlled trial...
- Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex
James C Fredenburgh
Henderson Research Centre and McMaster University, Hamilton, Ontario, Canada
J Biol Chem 283:2470-7. 2008
..Thus, bivalent binding of thrombin to gamma(A)/gamma'-fibrin protects thrombin from inhibition, raising the possibility that gamma(A)/gamma'-fibrin serves as a reservoir of active thrombin that renders thrombi thrombogenic...
- Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Jack Hirsh
Henderson Research Centre, Hamilton Civic Hospitals, 711 Concession Street, Hamilton, Ontario, Canada
Chest 133:141S-159S. 2008
..Three parenteral direct thrombin inhibitors and danaparoid are approved as alternatives to heparin in HIT patients...
- Ximelagatran: the first oral direct thrombin inhibitor
Mark A Crowther
McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
Expert Opin Investig Drugs 13:403-13. 2004
..It will also review the pharmacology of ximelagatran, discuss the clinical trial results with ximelagatran and provide perspective on the advantages and potential limitations of ximelagatran...
- Inhibition of osteolytic bone metastasis by unfractionated heparin
Colin K Yee
Department of Pathology and Molecular Medicine, McMaster University and the Henderson Research Center, 711 Concession Street, Hamilton, Ontario, Canada, L8V 1C3
Clin Exp Metastasis 25:903-11. 2008
..Based on these observations, we conclude that heparin inhibits the ability of tumour cells to metastasize to bone and that as such, prevents tumour cell-induced decreases in bone strength...
- An update on new anticoagulants
Lori-Ann Linkins
McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada L8V 1C3
Curr Drug Targets Cardiovasc Haematol Disord 3:287-300. 2003
....
- Prevention and treatment of venous thromboembolism during pregnancy
Jeffrey I Weitz
Medicine and Biochemistry, McMaster University, 711 Concession Street, Hamilton, Ontario, Canada
Catheter Cardiovasc Interv 74:S22-6. 2009
..Randomized clinical trials are needed to identify the optimal strategies for prevention and treatment of VTE in pregnancy...
- New anticoagulants
Jack Hirsh
Henderson Research Center, and McMaster University, Hamilton, Ontario, Canada
Blood 105:453-63. 2005
..Large phase 3 trials evaluating ximelagatran for the secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with atrial fibrillation have been completed...
